SGLT2 inhibitors therapy protects glucotoxicity-induced β-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress

Authors

Zeenat A. Shyr, Washington University School of Medicine in St. Louis
Zihan Yan, Washington University School of Medicine in St. Louis
Alessandro Ustione, Washington University School of Medicine in St. Louis
Erin M. Egan, Washington University School of Medicine in St. Louis
Maria S. Remedi, Washington University School of Medicine in St. Louis

Journal

PLoS One

Publication Date

1-1-2022

Volume

17

Issue

2

First Page

e258054

Document Type

Open Access Publication

DOI

10.1371/journal.pone.0258054

Rights and Permissions

Shyr ZA, Yan Z, Ustione A, Egan EM, Remedi MS (2022) SGLT2 inhibitors therapy protects glucotoxicity-induced β-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress. PLOS ONE 17(2): e0258054. https://doi.org/10.1371/journal.pone.0258054. Copyright: © 2022 Shyr et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Recommended Citation

Shyr, Zeenat A.; Yan, Zihan; Ustione, Alessandro; Egan, Erin M.; and Remedi, Maria S., "SGLT2 inhibitors therapy protects glucotoxicity-induced β-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress." PLoS One. 17, 2. e258054 (2022).
https://digitalcommons.wustl.edu/open_access_pubs/12063